Table 3.

Safety issues associated with the use of vaccines

Vaccine	Problem	Outcome	Refs
Killed respiratory syncytial virus	Enhanced disease after exposure to virus	Vaccine was never introduced onto the market	[51]
Oral polio virus	Reversion to virulence	Live vaccines now require larger and more stable deletions before approval	[52]
Live oral rotavirus	Intussusception	Vaccine no longer recommended and the required safety database has been expanded for future products	[9]
Inactivated measles	Atypical measles	Vaccine removed from the market	[53]
Intranasal flu with bacterial toxin adjuvant	Bell's palsy (facial paralysis)	Vaccine removed from the market	[54]
Whole-cell pertussis vaccine	Reactogenic	Removed from market in the majority of the developed world	[17]
Anthrax – cell-free filtrate product anthrax vaccine adsorbed	Reactogenic	Purified recombinant protein will be available in the near future	[55]
Swine flu	Guillain-Barré syndrome	Vaccination discontinued	[56]